Skip to content

Released Nov 16, 2026, after the close

10-Q filed Nov 16, 2026, 47 days after period end · 0001477932-26-007044

Q3 2026 · 10-Q
Revenue—
Net Income$4.62MN/M vs Q3 2025+5.1% vs Q2 2026
EPS, diluted—
Operating Income-$77,010N/M
Operating Cash Flowderived-$56,742N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2026Q3 2025
Net Income$4.62M-$46.16K

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Drugs Made In America Acquisition II Corp. · CIK 2040475 · Engraved from SEC EDGAR